A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly on Thursday said its daily obesity pill met the company's goals in the first of several late-stage trials, helping Type 2 diabetes patients lower their blood sugar and body weight and showing safety on par with popular injections on the market. The trial results are among the pharmaceutical industry's most closely watched studies of the year, as they bring Eli Lilly's experimental ...